New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

About this update from Assembly Biosciences, Inc.

[{"type":"image","alt":"Assembly Biosciences, Inc.","displaySize":"","headline":null,"caption":"Assembly Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MDnne0t7yPjd24iiqZ4Sig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8","width":300,"height":62}},"lazy":false},{"type":"text","content":"– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 –","length":122,"tagName":"p"},{"type":"text","content":"– Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 –","length":165,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the European Association for the Study of the Liver (EASL) Congress, taking place May 7-10, 2025, in Amsterdam, the Netherlands.","length":472,"tagName":"p"},{"type":"text","content":"“These two EASL poster presentations provide additional characterization of our therapeutic candidates in clinical development for viral hepatitis,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "Our late-breaker poster highlights ABI-6250’s preclinical profile and potential as a once-daily oral therapy for chronic HDV infection, a severe form of viral hepatitis with limited treatment options available. Additionally, in vitro data presented for ABI-4334 provide further insights into the potential for next-generation capsid assembly modulators to impact markers of chronic HBV infection. We look forward to sharing data from ongoing clinical studies for both candidates later this year.”","length":717,"tagName":"p"},{"type":"text","content":"ABI-6250: An oral viral entry inhibitor candidate for hepatitis D virus (HDV) infection","length":87,"tagName":"p"},{"type":"tex...

More updates from Assembly Biosciences, Inc.